Last reviewed · How we verify
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-6-microgram-dose)
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose (generic name: variant-adapted-bnt162b2-omicron-xbb-1-5-6-microgram-dose) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | variant-adapted-bnt162b2-omicron-xbb-1-5-6-microgram-dose |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose CI brief — competitive landscape report
- Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose
What is Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose?
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-6-microgram-dose) is a pharmaceutical drug developed by Pfizer Inc..
Who makes Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose?
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose?
variant-adapted-bnt162b2-omicron-xbb-1-5-6-microgram-dose is the generic (nonproprietary) name of Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose.
What development phase is Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose in?
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose is in Phase 2.